Rise in congestive heart failure fuels the growth of dilated cardiomyopathy market
Globally increase in the congestive heart failure cases, which leads to the increase in dilated cardiomyopathy cases. As per American Heart Association, in 2016, there were around 5.7 million adults in the U.S. who suffered from heart failure. However, there is no drug approved by FDA for the treatment of dilated cardiomyopathy furthermore, companies are investing in research and development of new drugs such as ARRY-797 and Ixmyelocel-T, which is expected to support the growth of dilated cardiomyopathy market. Major challenges for DCM market are increased use of defibrillators, pacemaker, and lack of proper drugs.
Developed regions are major growth engine of dilated cardiomyopathy market
Dilated cardiomyopathy market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East and Africa. North America has shown significant growth in DCM market due to increase in congestive heart failure cases. Europe is the second largest market of DCM as per, European Heart Network 2017 report, there are around 3.9 million deaths caused by cardiovascular disease in Europe and more than 1.8 million deaths in the Europe Union. Asia Pacific is the third largest market and expected to grow at a higher rate due to increased awareness of cardiovascular disease and demand of generic drugs is expected to support the growth of DCM market.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients